Clazosentan, a novel endothelin A antagonist, improves cerebral blood flow and behavior after traumatic brain injury

Neurological Research

Volumn 33, Issue 2, 2011, Pages 208-213

  Kreipke, Christian W ^a,b   Rafols, José A ^a,b   Reynolds, Christian A ^a   Schafer, Steven ^a   Marinica, Alex ^a   Bedford, Christopher ^a   Fronczak, Michael ^a   Kuhn, Donald ^a,b   Armstead, William M ^c  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Drug therapy; Endothelin; Microcirculation

Indexed keywords

CLAZOSENTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; BRAIN BLOOD FLOW; BRAIN PERFUSION; COGNITION; CONTROLLED STUDY; DRUG EFFICACY; MALE; MAZE TEST; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; RAT; SPIN LABELING; TRAUMATIC BRAIN INJURY; TREATMENT OUTCOME;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN INJURIES; CEREBROVASCULAR CIRCULATION; CEREBROVASCULAR DISORDERS; COGNITION DISORDERS; DIOXANES; DISEASE MODELS, ANIMAL; MALE; MAZE LEARNING; PYRIDINES; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ENDOTHELIN A; SULFONAMIDES; TETRAZOLES; VASODILATOR AGENTS;

EID: 79951897567     PISSN: 01616412     EISSN: None     Source Type: Journal    
DOI: 10.1179/016164111X12881719352570     Document Type: Article

References (25)

1. Mendelow AD, Teasdale GM. Pathophysiology of head injuries. Br J Surg 1983;70:641-50. (Pubitemid 14248225)
2. Ikeda Y, Long DM. The molecular basis of brain injury and brain edema: the role of oxygen free radicals. Neurosurgery 1990;27:1-11. (Pubitemid 20226076)
3. Gennarelli TA. Mechanisms of brain injury. J Emerg Med 1993;11:5-11. (Pubitemid 23054993)
4. Büki A, Povlishock JT. All roads lead to disconnection? - Traumatic axonal injury revisited. Acta Neurochir 2006;148:181-93. (Pubitemid 43139150)
5. Li XY, Feng DF. Diffuse axonal injury: novel insights into detection and treatment. J Clin Neurosci 2009;16:614-9.
6. Bouma GJ, Muizelaar JP. Cerebral blood flow, cerebral blood volume, and cerebrovascular reactivity after severe head injury. J Neurotrauma 1992;1:333-48.
7. Rafols JA. Editorial: microvascular and neuronal responses in a model of diffuse brain injury: therapeutic implications. Neurol Res 2007;29:337-8. (Pubitemid 47196050)
8. Povlishock JT. The classification of traumatic brain injury (TBI) for targeted therapies. J Neurotrauma 2008;25:717-8.
9. Armstead WM. Role of endothelin in pial artery vasoconstriction and altered responses to vasopressin after brain injury. J Neurosurg 1996;85:901-7. (Pubitemid 26362156)
10. + channel function after brain injury. Am J Physiol 1997;273:2639-47.
11. Kasemsri T, Armstead WM. Endothelin production links superoxide generation to altered opioid-induced pial artery vasodilation after brain injury in pigs. Stroke 1997;28:190-6.
12. Armstead WM. Role of endothelin-1 in age-dependent cerebrovascular hypotensive responses after brain injury. Am J Physiol 1999;277:1884-94.
13. + channel functional impairment after brain injury. J Neurotrauma 2001;18:1039-48.
14. Kreipke CW. Differential effects of endothelin receptor A and B antagonism on cerebral hypoperfusion following traumatic brain injury. Neurol Res 2009;32:209-14.
15. Reynolds CA, Rafols JA, Schafer S, et al. Differential effects of endothelin receptor A and B antagonism on behavioral outcome following traumatic brain injury. Neurol Res 2010; to be published.
16. Marmarou A, Foda MA, van den Brink W, Campbell J, Kita H, DemetriadouK. A new model of diffuse brain injury in rats. Part I: Pathophysiology and biomechanics. J Neurosurg 1994;80:291-300.
17. Schmued LC, Albertson C, Slikker W Jr. Fluoro-Jade: a novel fluorochrome for the sensitive and reliable histochemical localization of neuronal degeneration. Brain Res 1997;75:37-46. (Pubitemid 27122134)
18. Lüscher TF, Wenzel RR. Endothelin and endothelin antagonists: pharmacology and clinical implications. Agents Actions Suppl 1995;45:237-53.
19. Benigni A, Remuzzi G. Endothelin antagonists. Lancet 1999;353:133-8. (Pubitemid 29088093)
20. Krum H, Liew D. Current status of endothelin blockade for the treatment of cardiovascular and pulmonary vascular disease. Curr Opin Investig Drugs 2003;4:298-302. (Pubitemid 36526741)
21. Roux S, Breu V, Giller T, Neidhart W, Ramuz H, Coassolo P, et al. Ro 61-1790, a new hydrosoluble endothelin antagonist: general pharmacology and effects on experimental cerebral vasospasm. J Pharmacol Exp Ther 1997;283:1110-8. (Pubitemid 28016483)
22. Sato M, Noble LJ. Involvement of the endothelin receptor subtype A in neuronal pathogenesis after traumatic brain injury. Brain Res 1998;809:39-49. (Pubitemid 29003424)
23. Dawson DA, Sugano H, McCarron RM, Hallenbeck JM, Spatz M. Endothelin receptor antagonist preserves microvascular perfusion and reduces ischemic brain damage following permanent focal ischemia. Neurochem Res 1999;24:1499-505.
24. Görlach C, Hortobágyi T, Hortobágyi S, Benyó Z, Wahl M. Inhibition of endothelin-1 by the competitive ET(A) receptor antagonist Ro 61-1790 reduces lesion volume after cold injury in the rat. Pflugers Arch 2001;44:844-9. (Pubitemid 32186553)
25. Uhlmann D. Clazosentan (Actelion). Curr Opin Investig Drugs 2006;7:272-81.